This bill creates a new position called the Chief Pharmaceutical Trade Negotiator within the U.S. Trade Representative's office to focus specifically on pharmaceutical trade issues. The bill's main concern is that wealthy foreign countries are keeping drug prices artificially low through government price controls, which the bill argues unfairly shifts the cost of developing new medicines onto American patients and taxpayers.

Here's what the bill does in practical terms: It requires the U.S. government to annually review and publish a report on how wealthy countries regulate pharmaceutical prices and whether their policies are fair to American drug manufacturers. The bill specifically looks for practices that don't reflect market prices, prevent American companies from selling drugs in those countries, or discourage innovation. If the government finds that a country is engaging in what it considers unfair practices, it has 30 days to develop a response plan, which could include launching trade investigations or taking other trade actions against that country.

Essentially, this bill gives the U.S. government new tools and a dedicated official to push back against what it sees as other wealthy nations taking advantage of American pharmaceutical innovation by refusing to pay market prices for drugs. The bill's supporters argue this protects American innovation and ensures other countries contribute fairly to the cost of developing new medicines, while critics might worry it could lead to higher drug prices globally or trade tensions with allied nations.